INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PLYMOUTH MEETING, Pa., Jan. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that Dr. Jacqueline Shea, INOVIO's President and CEO, and Dr. Michael Sumner, Chief Medical Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

Oppenheimer 35th Annual Healthcare Life Sciences Conference Date: Wednesday, February 12, 2025Time: 3:20 – 3:50 pm ETFormat: Presentation

During the conference, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.

A webcast of the presentation will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. A replay of the webcast will be available for 90 days after the date of the presentation.

About INOVIOINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

ContactsMedia: Jennie Willson, (267) 429-8567, communications@inovio.com Investors: Peter Vozzo, ICR Healthcare, 443-213-0505, investor.relations@inovio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302363750.html

SOURCE INOVIO Pharmaceuticals, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

INO